AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.